NBTX (NBTX) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving NBTX (NBTX) right now is Johnson & Johnson partnership: J&J's Janssen unit holds a global license to NBTXR3 and now covers most costs of the pivotal Phase 3 program, validating the science and de-risking spend. Revenue (FY2025) is ~$36M (~EUR 32.6M, largely J&J-agreement, non-product). If that keeps playing out, the setup is favourable; the risk to it is the dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. No one can predict where NBTX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive NBTX (NBTX) higher?
1. Johnson & Johnson partnership
J&J's Janssen unit holds a global license to NBTXR3 and now covers most costs of the pivotal Phase 3 program, validating the science and de-risking spend. The deal carries potential milestone payments reported around $1.77 billion for the first programs plus royalties, so success would deliver large non-dilutive cash flows. Having a large-cap pharma sponsor also lends operational scale that a small biotech could not fund alone.
2. NANORAY-312 head and neck readout
NANORAY-312 is the registrational Phase 3 study in locally advanced head and neck squamous cell carcinoma, now J&J-sponsored, and its data is the single biggest catalyst for the stock. Management amended the design to remove the interim analysis and pull the final analysis forward, with a readout expectation communicated for the 2026 to 2027 window. A positive result would open a U.S. regulatory filing and a first potential approval.
3. Pipeline expansion beyond head and neck
Early Phase 2 CONVERGE data in stage 3 inoperable non-small cell lung cancer showed an encouraging overall response rate (around 85.7 percent in a very small initial patient group) when NBTXR3 was combined with chemoradiotherapy and immunotherapy. Additional tumor types and an Asia collaboration (LianBio) broaden the addressable opportunity. Each new indication is optionality layered on top of the core head and neck program.
4. Extended cash runway
After a roughly 86 million euro follow-on offering in May 2026 on top of prior royalty financing, the company has guided to a cash runway reaching toward 2029. A longer runway reduces the near-term risk of a forced, deeply dilutive raise ahead of key data. It gives Nanobiotix room to reach pivotal readouts without an urgent financing overhang.
What could weigh on NBTX?
The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. As a clinical-stage biotech, Nanobiotix funds itself through partnership payments and equity raises, so continued losses and further share dilution are likely until (and unless) a product is approved. The valuation of roughly $1.5 billion already embeds substantial expectation of success, leaving little margin for disappointment. Concentration is acute because a large share of value depends on one molecule and one partner, so a strategic shift by J&J would be highly damaging. Being a foreign issuer listed via ADS also adds currency, reporting-timing, and liquidity considerations for U.S. holders.
Where NBTX trades today
A forecast starts from where the stock actually is. These are NBTX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for NBTX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a NBTX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the NBTX guide and whether NBTX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the NBTX outlook
The bottom line: what is driving NBTX (NBTX) is Johnson & Johnson partnership, with revenue (fy2025) at ~$36M (~EUR 32.6M, largely J&J-agreement, non-product). If that keeps playing out the setup is favourable; the risk is the dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. No one can predict the price, so treat any NBTX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around NBTX with Walnut
Use NBTX as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for NBTX (NBTX)?
+
No one can reliably predict where NBTX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push NBTX higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive NBTX higher?
+
The main growth drivers are Johnson & Johnson partnership; NANORAY-312 head and neck readout; Pipeline expansion beyond head and neck. Whether they play out is the real question, not a guaranteed path.
What are the risks to NBTX?
+
The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. As a clinical-stage biotech, Nanobiotix funds itself through partnership payments and equity raises, so continued losses and further share dilution are likely until (and unless) a product is approved. The valuation of roughly $1.5 billion already embeds substantial expectation of success, leaving little margin for disappointment. Concentration is acute because a large share of value depends on one molecule and one partner, so a strategic shift by J&J would be highly damaging. Being a foreign issuer listed via ADS also adds currency, reporting-timing, and liquidity considerations for U.S. holders.
Will NBTX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. NBTX's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is NBTX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the NBTX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.